Lineage Cell Therapeutics Stock Forecast, Price & News

+0.13 (+5.37 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume5.32 million shs
Average Volume1.41 million shs
Market Capitalization$427.02 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive LCTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Lineage Cell Therapeutics logo

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Ca


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.37 out of 5 stars

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Frequently Asked Questions

Is Lineage Cell Therapeutics a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lineage Cell Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Lineage Cell Therapeutics stock.
View analyst ratings for Lineage Cell Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Lineage Cell Therapeutics?

Wall Street analysts have given Lineage Cell Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Lineage Cell Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Lineage Cell Therapeutics' next earnings date?

Lineage Cell Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Lineage Cell Therapeutics

How were Lineage Cell Therapeutics' earnings last quarter?

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) released its earnings results on Thursday, August, 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.03). The firm earned $0.51 million during the quarter, compared to the consensus estimate of $1.05 million. Lineage Cell Therapeutics had a negative net margin of 652.38% and a negative trailing twelve-month return on equity of 17.20%.
View Lineage Cell Therapeutics' earnings history

What price target have analysts set for LCTX?

6 brokers have issued 1-year price targets for Lineage Cell Therapeutics' stock. Their forecasts range from $4.00 to $8.00. On average, they expect Lineage Cell Therapeutics' share price to reach $6.00 in the next twelve months. This suggests a possible upside of 135.3% from the stock's current price.
View analysts' price targets for Lineage Cell Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Lineage Cell Therapeutics' key executives?

Lineage Cell Therapeutics' management team includes the following people:
  • Brian M. Culley, President, Chief Executive Officer & Director
  • Kevin L. Cook, Chief Financial & Accounting Officer
  • Gary S. Hogge, Senior Vice President-Clinical & Medical Affairs
  • François Binette, Global Head-Research & Development
  • Derek Kelaita, Vice President-Business Development

Who are some of Lineage Cell Therapeutics' key competitors?

What other stocks do shareholders of Lineage Cell Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lineage Cell Therapeutics investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Novan (NOVN), Pennsylvania Real Estate Investment Trust (PEI), Cannabics Pharmaceuticals (CNBX), Enerplus (ERF), KushCo (KSHB) and Zosano Pharma (ZSAN).

What is Lineage Cell Therapeutics' stock symbol?

Lineage Cell Therapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "LCTX."

Who are Lineage Cell Therapeutics' major shareholders?

Lineage Cell Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.11%), Vanguard Group Inc. (3.83%), Defender Capital LLC. (3.11%), Geode Capital Management LLC (1.40%), JPMorgan Chase & Co. (1.17%) and State Street Corp (1.12%). Company insiders that own Lineage Cell Therapeutics stock include Angus C Russell and Brian M Culley.
View institutional ownership trends for Lineage Cell Therapeutics

Which institutional investors are selling Lineage Cell Therapeutics stock?

LCTX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Cubist Systematic Strategies LLC, Creative Planning, Bridgeway Capital Management LLC, Susquehanna International Group LLP, Wealth Architects LLC, and Bank of America Corp DE. Company insiders that have sold Lineage Cell Therapeutics company stock in the last year include Angus C Russell, and Brian M Culley.
View insider buying and selling activity for Lineage Cell Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Lineage Cell Therapeutics stock?

LCTX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., State Street Corp, Northern Trust Corp, Geode Capital Management LLC, Vanguard Group Inc., DekaBank Deutsche Girozentrale, and Nuveen Asset Management LLC.
View insider buying and selling activity for Lineage Cell Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Lineage Cell Therapeutics?

Shares of LCTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lineage Cell Therapeutics' stock price today?

One share of LCTX stock can currently be purchased for approximately $2.55.

How much money does Lineage Cell Therapeutics make?

Lineage Cell Therapeutics has a market capitalization of $427.02 million and generates $1.83 million in revenue each year. The company earns $-20,650,000.00 in net income (profit) each year or ($0.13) on an earnings per share basis.

How many employees does Lineage Cell Therapeutics have?

Lineage Cell Therapeutics employs 52 workers across the globe.

What is Lineage Cell Therapeutics' official website?

The official website for Lineage Cell Therapeutics is www.lineagecell.com.

Where are Lineage Cell Therapeutics' headquarters?

Lineage Cell Therapeutics is headquartered at 2173 SALK AVENUE SUITE 200, CARLSBAD CA, 92008.

How can I contact Lineage Cell Therapeutics?

Lineage Cell Therapeutics' mailing address is 2173 SALK AVENUE SUITE 200, CARLSBAD CA, 92008. The company can be reached via phone at (510) 521-3390 or via email at [email protected].

This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.